Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Oncotarget|March 10, 2016
Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapySimon J Dovedi, Amy L Adlard, Yosuke Ota, et al.
The New England Journal of Medicine|June 6, 2019
Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock-Ah Im, Yen-Shen Lu, Aditya Bardia, et al.
Nature Communications|May 4, 2019
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF<sup>V600E</sup> amplification whereas KRAS<sup>G13D</sup> amplification promotes EMT-chemoresistanceMatthew J Sale, Kathryn Balmanno, Jayeta Saxena, et al.
Molecular Cancer Therapeutics|September 20, 2019
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses PreclinicallyLucy C Riches, Antonio G Trinidad, Gareth Hughes, et al.
Cancer Research|December 24, 2009
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activityChristine M Chresta, Barry R Davies, Ian Hickson, et al.
Journal of Medicinal Chemistry|January 15, 2025
Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACsMarisa Actis, Joel Cresser-Brown, Elizabeth A Caine, et al.
Human Molecular Genetics|February 10, 2006
Regional and cellular gene expression changes in human Huntington's disease brainAngela Hodges, Andrew D Strand, Aaron K Aragaki, et al.
Cancer Research|November 10, 2022
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy ResistanceMassimiliano Mellone, Klaudia Piotrowska, Giulia Venturi, et al.
The Lancet. Oncology|May 29, 2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Seock-Ah Im, Marco Colleoni, et al.
Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.
Pageof 7